<- Go Home
Ikena Oncology, Inc.
Ikena Oncology, Inc., an oncology company, focuses on developing therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. It develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Market Cap
$68.5M
Volume
183.2K
Cash and Equivalents
$36.8M
EBITDA
-$47.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$24.9M
Profit Margin
N/A
52 Week High
$1.94
52 Week Low
$0.97
Dividend
N/A
Price / Book Value
0.58
Price / Earnings
-1.64
Price / Tangible Book Value
0.58
Enterprise Value
-$38.9M
Enterprise Value / EBITDA
0.90
Operating Income
-$48.3M
Return on Equity
30.49%
Return on Assets
-19.87
Cash and Short Term Investments
$114.1M
Debt
$6.6M
Equity
$118.3M
Revenue
N/A
Unlevered FCF
-$26.6M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium